ThromboGenics Ltd. (THR.BR) and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule  
12/16/2011 7:20:56 AM

LUND, Sweden & LEUVEN, Belgium--(BUSINESS WIRE)--ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe.